Payment overview · 2025
General Payments
$113.40
1 reported records · 1 companies
Healthcare provider profile · identity verified
David Lee Conner, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARIBOU, ME · NPI 1093801631
Verified facts
What the public records show
CMS Open Payments records show David Lee Conner, MD received $113.40 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.40 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $113.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $113.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 213 | 48 |
| Lisinopril | Lisinopril | 210 | 51 |
| Metformin Hcl | Metformin Hcl | 178 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 31 |
| Farxiga | Dapagliflozin Propanediol | 139 | 27 |
| Gabapentin | Gabapentin | 136 | 30 |
| Buprenorphine Hcl | Buprenorphine Hcl | 131 | 13 |
| Omeprazole | Omeprazole | 130 | 36 |
| Methadone Hcl | Methadone Hcl | 127 | 11 |
| Spironolactone | Spironolactone | 119 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 25 |
| Ezetimibe | Ezetimibe | 111 | 29 |
| Eliquis | Apixaban | 108 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 23 |
| Pregabalin | Pregabalin | 106 | 27 |
| Alprazolam | Alprazolam | 103 | 14 |
| Trulicity | Dulaglutide | 100 | 18 |
| Carvedilol | Carvedilol | 91 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 11 |
| Indapamide | Indapamide | 77 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Clonidine Hcl | Clonidine Hcl | 65 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 64 | suppressed |
| Lorazepam | Lorazepam | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Losartan Potassium | Losartan Potassium | 60 | 16 |
| Furosemide | Furosemide | 59 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 55 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 54 | 11 |
| Valsartan | Valsartan | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | 11 |
| Prednisone | Prednisone | 44 | 26 |
| Vascepa | Icosapent Ethyl | 44 | 11 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Topiramate | Topiramate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Sublocade | Buprenorphine | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $113.40 · 1 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error